Moderna stock crashes 25%, loses about $24 billion after cancer vaccine data leak

Moderna’s stock price dropped over 25% after trial results for its personalized melanoma vaccine with Merck were disclosed. The decline erased approximately $24 billion from…

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (economictimes.indiatimes.com)